New device could catch colon cancers that stool tests miss
NCT ID NCT07623902
First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time
Summary
This study tests a device called Gixam to see if it can find precancerous growths or colon cancer in people aged 45-84 who had a negative stool test (FIT). About 1,436 participants will use the Gixam device, take a home stool test, and then get a standard colonoscopy. The goal is to see if Gixam catches cancers that stool tests miss, improving early detection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,436 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 84 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants aged ≥45 - ≤84 years. 2. Able to provide a signed informed consent. 3. Considered by a physician or healthcare provider as being of 'average risk' for CRC. 4. Scheduled for a screening colonoscopy at investigation site. Exclusion Criteria: 1. Undergoing colonoscopy for investigation of symptoms. 2. Has undergone colonoscopy within preceding nine (9) years except for a failed colonoscopy due to poor bowel preparation. Failed colonoscopy must have been within the past year and without therapeutic intervention. 3. Positive FIT or Fecal Occult Blood Test (FOBT) result within the preceding eleven (11) months. 4. Positive Cologuard, Sheild, ColoSense or Epi proColon test within the preceding three (3) years. 5. History of colorectal cancer. 6. Family history of colorectal cancer, defined as having one or more first- degree relatives (parent, sibling, or child) with CRC at any age. 7. Participant has a diagnosis or medical / family history of any of the following conditions, including: * Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome) * Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome") * Other hereditary cancer syndromes including but not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis. 8. Participant has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease. 9. Participants with a disability to extend their tongue. 10. Participants with tongue tremor. 11. Participants with tongue piercing. 12. Participants that had a dental visit in the 7 days prior to the Gixam test. 13. Participants that have taken antibiotics or anti-fungal medications in the 14 days prior to the Gixam test. 14. Participants that have taken probiotics in the 14 days prior to the Gixam test. 15. Participant is pregnant. 16. Participant has any condition that in the opinion of the Investigator should preclude participation in the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Colorectal neoplasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Blue Ridge Medical Research
RECRUITINGLynchburg, Virginia, 24502, United States
-
Comprehensive Gastrointestinal Health, LLC
ACTIVE_NOT_RECRUITINGNorthbrook, Illinois, 60062, United States
-
East View Medical Research, LLC
RECRUITINGMobile, Alabama, 36606, United States
-
Gastro Care Institute
RECRUITINGLancaster, California, 93534, United States
-
Great Lakes Gastroenterology Research, LLC
RECRUITINGMentor, Ohio, 44060, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
Orlando Gastroenterology, PA
RECRUITINGOrlando, Florida, 32835, United States
-
Westchester Putnam Gastro
RECRUITINGCarmel, New York, 10549, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a stronger flu shot boost immunity in older adults?
- Switching stomach drugs after transplant may tame a deadly immune attack
- Can a fiber supplement reshape the small Intestine's hidden microbiome?
- Mailed stool tests could boost colon cancer screening
- Could a simple fibre supplement reshape your gut microbiome?
- Could a gut bacteria transplant restore hair in alopecia areata?